Saturna Capital Corp Purchases 1,618 Shares of Edwards Lifesciences Co. (NYSE:EW)

Saturna Capital Corp grew its position in Edwards Lifesciences Co. (NYSE:EW) by 7.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,534 shares of the medical research company’s stock after purchasing an additional 1,618 shares during the quarter. Saturna Capital Corp’s holdings in Edwards Lifesciences were worth $1,619,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Park Avenue Securities LLC lifted its position in Edwards Lifesciences by 0.5% during the 2nd quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after buying an additional 108 shares in the last quarter. City State Bank lifted its position in Edwards Lifesciences by 16.5% during the 2nd quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after buying an additional 130 shares in the last quarter. Stableford Capital II LLC lifted its position in Edwards Lifesciences by 2.7% during the 2nd quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock worth $533,000 after buying an additional 159 shares in the last quarter. Purus Wealth Management LLC lifted its position in Edwards Lifesciences by 5.2% during the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock worth $297,000 after buying an additional 160 shares in the last quarter. Finally, Busey Bank lifted its position in Edwards Lifesciences by 1.9% during the 2nd quarter. Busey Bank now owns 8,838 shares of the medical research company’s stock worth $816,000 after buying an additional 165 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.1 %

Shares of Edwards Lifesciences stock opened at $65.90 on Wednesday. The business has a fifty day simple moving average of $67.47 and a two-hundred day simple moving average of $76.51. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a market capitalization of $38.87 billion, a price-to-earnings ratio of 9.50, a P/E/G ratio of 3.75 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter last year, the firm posted $0.59 EPS. The company’s quarterly revenue was up 8.9% on a year-over-year basis. Research analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total value of $333,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,133,916.72. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,250 shares of company stock valued at $2,416,588. 1.27% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on EW shares. Baird R W downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Morgan Stanley restated an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 11th. Daiwa Capital Markets upgraded shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Jefferies Financial Group downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their target price for the company from $85.00 to $70.00 in a research report on Wednesday, September 18th. Finally, UBS Group decreased their price target on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Tuesday, September 10th. Seventeen investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $75.67.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.